TB Drug Accelerator Program

Program Objectives

The TB Drug Accelerator Programme aims to speed up the discovery and development of novel compounds against tuberculosis (TB).

The TBDA aims to develop five new pre-clinical drug candidates with treatment-shortening potential within five years and proof-of-concept for a one-month three-drug regimen within ten years. The TBDA aims to develop five new pre-clinical drug candidates with treatment-shortening potential within five years and proof-of-concept for a one-month three-drug regimen within ten years. Copyright AstraZeneca

What are the health needs and challenges?

Despite significant progress in combatting tuberculosis (TB), TB remains one of the leading causes of death worldwide. According to WHO, in 2014 TB killed 1.5 million people (1.1 million HIV-negative and 0.4 million HIV-positive). In recent years, the emergence of multi-drug resistant TB and extensively drug-resistant TB has increased pressure to urgently control the disease and epidemic, particularly in countries with a high rate of HIV. As a result of years of inadequate diagnosis and treatment, these types of drug-resistant TB are more difficult and costly to treat, highlighting the urgent need for new, better, faster-acting treatments.

Description of partnership activities and how they address needs and challenges

Launched in August 2012, TB Drug Accelerator (TBDA) is a ground-breaking partnership between eight pharmaceutical companies and seven research organizations with support from the Bill &Melinda Gates Foundation.

Aided by nearly U.S. $20 million (approx. €16.5 million) from the Gates Foundation, the TBDA aims to develop five new pre-clinical drug candidates with treatment-shortening potential within five years and proof-of-concept for a one-month three-drug regimen within ten years. TBDA targets the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA is to create a TB drug regimen that cures patients in only one month, rather than the 6 months now needed for treatment.

Corresponding principle in the declaration

“We support new ways of working such as open collaborations between industry and public researchers to overcome the scientific challenges of creating new antibiotics and diagnostics”.

Read full Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR)


Partnership information

Company(ies) AbbVie , AstraZeneca , Bayer , Eisai , Eli Lilly and Company , GlaxoSmithKline , MSD , Sanofi

Partner(s) Bill and Melinda Gates Foundation, Global Alliance for TB Drug Development (TB Alliance), Infectious Disease Research Institute (IDRI), Texas A&M University, US National Institutes of Health (NIH), Weill Medical College, Cornell University

Type of Partner(s) Academia / Hospitals, Government, NGOs, PDPs

Therapeutic Focus Infectious Diseases

Disease(s) Drug-Resistant Infections (AMR), Tuberculosis

Program Type(s) Research & Development - Development of Treatments, Research & Development - Operations Research

Targeted Population(s) Men, Patients in needs of treatment, Women

Region(s) East Asia & Pacific, North America, South Asia, Sub-Saharan Africa

Number of Countries 79

Country(ies) Angola, Bangladesh, Benin, Botswana, Brunei, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, China, Comoros, Congo, Cook Islands, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Fiji, Gabon, Ghana, Guinea, Guinea-Bissau, India, Indonesia, Japan, Kenya, Kiribati, Lao PDR, Lesotho, Liberia, Madagascar, Malawi, Malaysia, Mali, Marshall Islands, Mauritania, Mauritius, Micronesia, Mongolia, Mozambique, Myanmar, Namibia, Niger, Nigeria, Niue, Palau, Papua New Guinea, Philippines, Rwanda, Samoa, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Singapore, Solomon Islands, Somalia, South Africa, South Korea, South Sudan, Sudan, Swaziland, Tanzania, Thailand, The Gambia, Timor-Leste, Togo, Tonga, Tuvalu, Uganda, United States of America, Vanuatu, Vietnam, Zambia, Zimbabwe

Start Date 2012

More information TB Alliance Gates Foundation

Anticipated completion date Ongoing

« ...We seek a common goal—to give patients and physicians significantly more effective treatments for TB and drug-resistant TB. Without new regimens, we cannot stop this global pandemic. »

Mel Spigelman, M.D., President and Chief Executive Officer, TB Alliance